JP2024516376A5 - - Google Patents
Info
- Publication number
- JP2024516376A5 JP2024516376A5 JP2023563189A JP2023563189A JP2024516376A5 JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5 JP 2023563189 A JP2023563189 A JP 2023563189A JP 2023563189 A JP2023563189 A JP 2023563189A JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dna
- section
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176225P | 2021-04-17 | 2021-04-17 | |
| US63/176,225 | 2021-04-17 | ||
| PCT/US2022/025075 WO2022221696A1 (en) | 2021-04-17 | 2022-04-15 | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516376A JP2024516376A (ja) | 2024-04-15 |
| JP2024516376A5 true JP2024516376A5 (https=) | 2025-04-22 |
Family
ID=81581217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563189A Pending JP2024516376A (ja) | 2021-04-17 | 2022-04-15 | Ｄｎａ依存性プロテインキナーゼの阻害剤ならびにその組成物及び使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240300977A1 (https=) |
| EP (1) | EP4323360A1 (https=) |
| JP (1) | JP2024516376A (https=) |
| KR (1) | KR20240017791A (https=) |
| CN (1) | CN117940426A (https=) |
| AU (1) | AU2022258733A1 (https=) |
| BR (1) | BR112023021429A2 (https=) |
| CA (1) | CA3216875A1 (https=) |
| CL (1) | CL2023003079A1 (https=) |
| CO (1) | CO2023015478A2 (https=) |
| CR (1) | CR20230535A (https=) |
| IL (1) | IL307740A (https=) |
| MX (1) | MX2023012236A (https=) |
| TW (1) | TW202309034A (https=) |
| WO (1) | WO2022221696A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| JP2026509874A (ja) * | 2023-03-13 | 2026-03-25 | インサイト・コーポレイション | キナーゼ阻害剤としての二環式尿素 |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| WO2025049432A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| JP6883653B2 (ja) | 2016-12-20 | 2021-06-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US20220009878A1 (en) | 2018-10-02 | 2022-01-13 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| BR112021010853A2 (pt) | 2018-12-05 | 2021-08-31 | Intellia Therapeutics, Inc. | Lipídios de amina modificados |
| CN114127044A (zh) | 2019-04-25 | 2022-03-01 | 英特利亚治疗股份有限公司 | 可电离的胺类脂质和脂质纳米颗粒 |
| EP3983542A2 (en) * | 2019-06-17 | 2022-04-20 | CRISPR Therapeutics AG | Methods and compositions for improved homology directed repair |
-
2022
- 2022-04-15 IL IL307740A patent/IL307740A/en unknown
- 2022-04-15 BR BR112023021429A patent/BR112023021429A2/pt not_active Application Discontinuation
- 2022-04-15 CN CN202280042815.9A patent/CN117940426A/zh active Pending
- 2022-04-15 WO PCT/US2022/025075 patent/WO2022221696A1/en not_active Ceased
- 2022-04-15 MX MX2023012236A patent/MX2023012236A/es unknown
- 2022-04-15 EP EP22721588.6A patent/EP4323360A1/en active Pending
- 2022-04-15 CR CR20230535A patent/CR20230535A/es unknown
- 2022-04-15 KR KR1020237039428A patent/KR20240017791A/ko active Pending
- 2022-04-15 JP JP2023563189A patent/JP2024516376A/ja active Pending
- 2022-04-15 CA CA3216875A patent/CA3216875A1/en active Pending
- 2022-04-15 TW TW111114469A patent/TW202309034A/zh unknown
- 2022-04-15 AU AU2022258733A patent/AU2022258733A1/en active Pending
- 2022-04-15 US US18/287,227 patent/US20240300977A1/en active Pending
-
2023
- 2023-10-16 CL CL2023003079A patent/CL2023003079A1/es unknown
- 2023-11-16 CO CONC2023/0015478A patent/CO2023015478A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516376A5 (https=) | ||
| US12559536B2 (en) | CD33 specific chimeric antigen receptors | |
| US12344651B2 (en) | CD19 and CD22 chimeric antigen receptors and uses thereof | |
| US20240316107A1 (en) | Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 | |
| KR102883631B1 (ko) | 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법 | |
| KR20180133480A (ko) | 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법 | |
| CN107922925A (zh) | 用于自然杀伤细胞扩增的方法 | |
| US12569516B2 (en) | Subject-specific tumor inhibiting cells and the use thereof | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| CN113660942A (zh) | 嵌合细胞因子受体 | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| CN114921417B (zh) | 双基因定点整合通用型car-t细胞的制备方法及其应用 | |
| US11859207B2 (en) | Artificial antigen-presenting cell prepared from HLA-null cell line by using multiplex CRISPR-CAS9 system and use thereof | |
| US20220202900A1 (en) | Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia | |
| CN118853582A (zh) | 基因编辑的肿瘤浸润淋巴细胞及其在免疫细胞治疗中的应用 | |
| AU2024224895A1 (en) | Methods for generating primary immune cells | |
| US20230190780A1 (en) | Methods for immunotherapy | |
| HK40062145B (zh) | 由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途 | |
| CN117778328A (zh) | 一种通用型bcma car-t细胞的增殖方法 | |
| CN116904514A (zh) | 用双aav载体同步定点基因编辑制备car-t细胞的方法 |